Aphasia Disease

Published Date : Nov 2023
Category : Neurodegenerative Disorders
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Examining the Changing Global Landscape of Aphasia Disease: Present Constraints and Prospects

More than any other medical condition, aphasia—the inability to communicate verbally following a stroke, brain injury, or other brain disease—has a detrimental effect on quality of life.

As per the National Institute on Deafness and Other Communication Disorders (NIDCD), 1 in every 272 Americans suffers from aphasia, with 180,000 new cases reported each year in the US. A third of the cases are thought to be related to cerebrovascular accidents. The most prevalent type is called global aphasia. Men and women experience CVA-related aphasia at similar rates. However, the incidence varies with age. Individuals under 65 years of age have a 15% risk of being impacted, while those over 85 years old have a 43% probability of getting the illness. Due to damage to the brain regions responsible for processing language, aphasia develops in 25–40% of stroke survivors.

Damage to the areas of the brain involved in language comprehension and production leads to aphasia.

Typical causes consist of strokes, which are the most frequent cause of aphasia, serious head trauma, and a brain tumor, progressive neurological disorders, such as dementia, are conditions that harm the brain and nervous system over time.

All ages are affected by aphasia, however, those over 65 are most likely to have it. This is because elderly persons are more likely to suffer from strokes and degenerative neurological problems.

Aphasia has four primary forms which include:

Broca's (Expressive) Aphasia- When a patient has expressive aphasia, they think and write what they want to convey, but they struggle with speaking it out.

Wernicke’s (Receptive) Aphasia- Speech and reading comprehension are impacted by receptive aphasia. Even when patients hear words spoken aloud or see words written on a page, they struggle to understand what is being said.

 Global Aphasia- The complete loss of language skills is known as global aphasia. The patient is incapable of writing, reading, or understanding speech.

Anomic or Amnesia Aphasia- When a patient has trouble pronouncing specific objects, persons, locations, or events correctly, it is referred to as anomic or amnesia aphasia.

A brain injury, usually to the left hemisphere, that impairs the operation of essential components of the language network causes aphasia, an acquired neurogenic language disease. Different levels of impairment are present in four main areas in aphasia expression in spoken language, compositional language understanding, and spoken language comprehension.

Diagnostic Analysis of Aphasia

Neurological Examination

A neuropsychological, speech-language, and neurological examination is performed by medical professionals. Tests gauge candidates' abilities in speech and language comprehension. In addition, they test recall, object recognition and naming, and other abilities.

Blood Tests

Blood tests are used to check for a wide range of conditions, including immune system issues, poisons, and toxins, particularly heavy metals like copper.

Imaging Tests

  • Magnetic Resonance Imaging- Primary progressive aphasia is diagnosed with a brain MRI. The test identifies brain shrinkage in particular brain regions. MRI scans can also identify tumors, strokes, and other disorders that impact brain activity.
  • PET Scan- PET scans are used to demonstrate how the brain functions. This test reveals issues with glucose metabolism in the language-related regions of the brain.
  • Electroencephalogram- A brain activity monitor is called an electroencephalogram, or EEG. Medical professionals identify and track brain-related disorders like aphasia by utilizing brain activity data. If a patient exhibits symptoms like convulsions or confusion, an EEG is performed.

Diagnostic Market Players and Diagnostic Products:

Diagnostic Market Players

Diagnostic Products

Siemens Healthineers


General Electric Company (GE Healthcare)

Discovery™ MI

Radiance Imaging system

Dopplex ATP

Philips Healthcare



Biograph mMR®

Cardinal Health, Inc.


AngioDymanics, Inc.



Treatment Analysis for Aphasia

  • Speech and Language Rehabilitation

The objective of speech and language therapy is to improve communication skills. The goal of therapy is to help the patient communicate in other ways, learn how to compensate for language deficits, and restore as much language as possible.

  • Medication

Aphasia is being studied as a possible treatment for a few medications. These include medications that could increase blood flow to the brain, speed up the brain's ability to heal or assist in replenishing the brain's depleted chemical supply (neurotransmitters). Several drugs have shown promise in small studies, including Galantamine (Razadyne ER), Donepezil (Aricept, Adlarity), Memantine (Namenda), and Piracetam. However, before these treatments are suggested, more research is required.

  • Non-Invasive Brain Stimulation

 The application of non-invasive brain stimulation (NIBS) methods to improve aphasia recovery has gained widespread acceptance. These methods include transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).

  • Transcranial Magnetic Stimulation (TMS)- TMS is a non-invasive technique for stimulating the brain that uses electromagnetic induction to alter neuronal firing patterns. Usually, a stimulation coil is placed over the scalp to deliver a brief, powerful current that causes a time-varying, perpendicular magnetic field to penetrate the scalp without attenuating.
  • Transcranial Direct Current Stimulation (tDCS)- tDCS is usually applied using surface sponge electrodes that have been soaked in saline, affixed to the scalp, and linked to a low-intensity direct current stimulator (1-2 mA). Because tDCS modifies the resting membrane potential of brain nerve cells, it either increases or decreases cortical excitability. The majority of tDCS research results in aphasia have been positive, suggesting that tDCS can support aphasia treatment.

Treatment Market Players and Treatment Products:

Treatment Market Players

Treatment Products

Kindred Healthcare, LLC

Namenda XR

Powerback Rehab


Benchmark Physical Therapy Institute


Relient Rehabilitation

Piracetam Tablets

Humanus Corporation

Razadyne® ER

Smart Speech Therapy


Therapy Solutions Inc.


Rehabilitation Associates, Inc.



Clinical Trail Assessment

The DiseaseLandscape Insights consultancy offers invaluable assistance with regard to upcoming market trends and the creation of novel pharmaceutical products. This support ensures regulatory compliance, increases the possibility of successful trial outcomes, and streamlines the planning and execution of clinical trials of novel drugs and therapies. It also helps to implement successful patient recruitment tactics.

The table below highlights the study titles of the ongoing clinical trials as well as the stages in which they are taking place.





Tau PET Imaging in Atypical Dementias

Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Speech Entrainment for Aphasia Recovery

Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1


Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer's Disease

Treating Primary Progressive Aphasia (PPA) Using High definition tDCS



The Safety and The Efficacy Evaluation of ET-STEM in Patients with Frontotemporal Dementia

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with Frontotemporal Dementia (FTD-GRN)



A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with Frontotemporal Dementia (FTD-GRN)

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects with a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)





DiseaseLandscape Insights (DLI) assists manufacturers in developing and implementing viable remedies to interrupt and manage Aphasia disease outbreaks. Furthermore, there is an increasing need for diagnostic tools, clinical evaluations, and innovative therapies because of greater awareness and estimated epidemics.

DiseaseLandscape Insights offers essential knowledge and expertise to major stakeholders involved in the production of therapeutic goods. DLI services make it easier for market participants to organize and carry out clinical trials for innovative medicines and pharmaceuticals, patient recruiting tactics, and regulatory compliance.

All in all, this encourages the leaders to perform qualitative research, explore the manufacturing organizations, and learn about raw material suppliers. DiseaseLandscape Insights assists all industry players to stay one step ahead and obtain a stronger foothold in the disease domain.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape